Mark Lackner Net Worth

The estimated Net Worth of Mark Lackner is at least $7.16 million dollars as of 1 February 2024. Mark Lackner owns over 1,585 units of IDEAYA Biosciences stock worth over $7,085,354 and over the last 5 years he sold IDYA stock worth over $72,242. In addition, he makes $0 as Senior Vice President et Head of Biology and Translational Sciences at IDEAYA Biosciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Lackner IDYA stock SEC Form 4 insiders trading

Mark has made over 5 trades of the IDEAYA Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,585 units of IDYA stock worth $18,291 on 1 February 2024.

The largest trade he's ever made was exercising 7,123 units of IDEAYA Biosciences stock on 16 June 2020 worth over $39,675. On average, Mark trades about 1,757 units every 167 days since 2020. As of 1 February 2024 he still owns at least 195,728 units of IDEAYA Biosciences stock.

You can see the complete history of Mark Lackner stock trades at the bottom of the page.

Mark Lackner biography

Dr. Mark Lackner Ph.D. serves as Senior Vice President, Head of Biology and Translational Sciences of the Company. From May 2018 to December 2018, he served as our Vice President, Head of Biology and Translational Sciences. Prior to joining us, Dr. Lackner worked at Genentech, a biotechnology company, from November 2004 to May 2018, in various positions in the Oncology Biomarker Development group, most recently as a Director and Principal Scientist. Prior to joining Genentech, Dr. Lackner worked at Exelixis, Inc. from 1999 through 2004 in oncology target identification and validation. Dr. Lackner received a Ph.D. from Stanford University in Developmental Biology. He completed postdoctoral studies at the University of California, Berkeley in the laboratory of Joshua Kaplan. Dr. Lackner obtained a B.S. and an M.S. in Biology from the University of Illinois at Urbana–Champaign.

How old is Mark Lackner?

Mark Lackner is 53, he's been the Senior Vice President et Head of Biology and Translational Sciences of IDEAYA Biosciences since 2018. There are 10 older and 7 younger executives at IDEAYA Biosciences. The oldest executive at IDEAYA Biosciences, Inc. is Wendy Yarno, 65, who is the Independent Director.

What's Mark Lackner's mailing address?

Mark's mailing address filed with the SEC is C/O ZENTALIS PHARMACEUTICALS, INC., 1359 BROADWAY, SUITE 801, NEW YORK, NY, 10018.

Insiders trading at IDEAYA Biosciences

Over the last 5 years, insiders at IDEAYA Biosciences have traded over $13,169,580 worth of IDEAYA Biosciences stock and bought 2,220,527 units worth $22,722,236 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Timothy M Shannon et X L.P.Canaan Partners X Llc.... On average, IDEAYA Biosciences executives and independent directors trade stock every 29 days with the average trade being worth of $2,196,906. The most recent stock trade was executed by Jason Throne on 27 June 2024, trading 53,484 units of IDYA stock currently worth $415,571.

What does IDEAYA Biosciences do?

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Complete history of Mark Lackner stock trades at Zentalis Pharmaceuticals, Llc et IDEAYA Biosciences

IDEAYA Biosciences executives and stock owners

IDEAYA Biosciences executives and other stock owners filed with the SEC include:

• Yujiro Hata,
  President, Chief Executive Officer, Director
• Paul Stone,
  Chief Financial Officer
• Yujiro S. Hata,
  Co-Founder, CEO, Pres & Director
• Michael Dillon,
  Senior Vice President, Chief Scientific Officer, Head of Research
• Paul A. Stone,
  Sr. VP, CFO & Principal Accounting Officer
• Jason S. Throne J.D., Esq.,
  Sr. VP, Gen. Counsel & Company Sec.
• Dr. Michael A. White Ph.D.,
  Sr. VP & Chief Scientific Officer
• Scott Morrison,
  Independent Director
• Jeffrey Stein,
  Independent Director
• Terry Rosen,
  Independent Director
• Wendy Yarno,
  Independent Director
• Tim Shannon,
  Independent Chairman of the Board
• Thilo Schroeder,
  Independent Director
• Garret Hampton,
  Independent Director
• Mick O'Quigley,
  Vice President, Development Operations
• Paul Barsanti,
  Vice President, Head - Drug Discovery
• Julie Patel,
  Vice President of Human Resources
• Jason Throne,
  Vice President, General Counsel, Corporate Secretary
• Andres Briseno,
  Vice President - Finance
• Mark Lackner,
  Senior Vice President, Head of Biology and Translational Sciences
• Dr. Matthew Maurer M.D.,
  VP and Head of Medical Affairs & Clinical Oncology
• Andres Ruiz Briseno CPA,
  VP and Head of Bus. Operations & IR
• Dr. Jeffrey Hager Ph.D.,
  Co-Founder & Member of the Scientific Advisory Board
• Partners L P/Ilbiotechnolog...,
  
• Ventures Iv, L.P.5 Am Co In...,
  
• John D Diekman,
  Director
• X L.P.Canaan Partners X Llc...,
  
• Julie Hambleton,
  SVP, Chief Medical Officer
• Jeffrey Hager,
  SVP, Chief Technology Officer
• Susan L. Kelley,
  
• Catherine J Mackey,
  
• Ventures Iv, L.P.5 Am Co In...,
  
• Michael Anthony White,
  Chief Scientific Officer
• Darrin Beaupre,
  Chief Medical Officer